Impact case study database
The impact case study database allows you to browse and search for impact case studies submitted to the REF 2021. Use the
search and filters below to find the impact case studies you are looking for.
Download all impact case studies (spreadsheet) (generating)
Download all impact case study tags (spreadsheet) (generating)
Waiting for server
Improving the clinical management of HIV and Hepatic Diseases worldwide: open access digital prescribing tools to optimise the management of drug-drug interactions
1. Summary of the impact
2. Underpinning research
3. References to the research
4. Details of the impact
5. Sources to corroborate the impact
Additional contextual information
Grant funding
| Grant number | Value of grant |
|---|---|
| INT-2015-8422 | £26,338 |
| Janssen | £10,000 |
| JANSSEN PHARMACEUTICALS (BELGIUM) | £20,000 |
| INT-2015-8422 | £0 |
| INT-2015-8422 | £23,010 |
| INT-2015-8422 | £47,337 |
| INT-19-13896 | £34,723 |
| INT-19-13896 | £34,723 |
| EASL | £8,542 |
| EASL | £7,803 |
| BMS | £15,000 |
| 38463705 | £10,000 |
| 38463705 | £10,000 |
| 38463705 | £14,000 |
| MERCK | £25,000 |
| JANSSEN-CILAG LIMITED | £10,000 |
| JANSSEN PHARMACEUTICALS (BELGIUM) | £22,875 |
| JANSSEN PHARMACEUTICALS (BELGIUM) | £22,628 |
| JANSSEN PHARMACEUTICALS (BELGIUM) | £10,000 |
| JANSSEN PHARMACEUTICALS (BELGIUM) | £20,000 |
| JANSSEN PHARMACEUTICALS (BELGIUM) | £45,000 |
| UoL Hepatitis drug interactions website | £28,720 |
| Gilead | £25,000 |
| ABBVIE LTD UK | £37,500 |
| ABBVIE LTD UK | £70,000 |
| ABBVIE LTD UK | £83,600 |
| ABBVIE LTD UK | £50,000 |
| ABBVIE LTD UK | £50,000 |
| ABBVIE LTD UK | £50,000 |
| ABBVIE LTD UK | £37,000 |
| ABBVIE LTD UK | £30,000 |
| ABBVIE LTD UK | £37,500 |
| AXSRA170441 | £10,000 |
| BRISTOL-MYERS SQUIBB BELGIUM | £11,111 |
| BMS | £15,000 |
| PO: 7300329540 | £40,000 |
| PO: 7300329540 | £40,000 |
| PO: 7300329540 | £44,058 |
| INT-2015-8422 | £26,338 |
| INT-2015-8422 | £23,011 |
| INT-2015-8422 | £23,011 |
| VERTEX PHARMACEUTICALS | £25,000 |
| JANSSEN PHARMACEUTICALS (BELGIUM) | £50,000 |
| JANSSEN PHARMACEUTICALS (BELGIUM) | £15,610 |
| Janssen | £25,000 |
| ABBVIE INC (USA) | £15,625 |
| ABBVIE INC (USA) | £15,625 |
| ABBVIE INC (USA) | £36,400 |
| Roche | £20,000 |
| Roche | £20,000 |
| BRISTOL-MYERS SQUIBB BELGIUM | £13,200 |
| Janssen | £20,000 |
| University of Liverpool | £30,547 |
| University of Liverpool | £21,719 |
| KP360 | £10,000 |
| KP360 | £20,000 |
| KP360 | £20,000 |
| KP360 | £50,000 |
| MR/V020498/1 | £66,177 |
| BXR10113 | £10,000 |
| INT-2015-8422 | £0 |
| INT-2015-8422 | £16,100 |
| MERCK SHARP & DOHME LTD | £20,000 |
| VERTEX PHARMACEUTICALS | £29,000 |
| VERTEX PHARMACEUTICALS | £30,000 |
| JANSSEN-CILAG LIMITED | £8,018 |
| Janssen | £10,000 |
| Gilead | £0 |
| GILEAD SCIENCES EUROPE | £21,387 |
| Gilead | £180,000 |
| GILEAD SCIENCES EUROPE | £180,000 |
| GILEAD SCIENCES EUROPE | £23,628 |
| GILEAD SCIENCES EUROPE | £35,774 |
| GILEAD SCIENCES EUROPE | £25,000 |
| Saye Khoo | £70,000 |
| Saye Khoo | £30,000 |
| University of Liverpool | £39,578 |
| INT-2015-8422 | £16,100 |
| INT-2015-8422 | £47,337 |
| INT-2015-8422 | £55,973 |
| GILEAD SCIENCES EUROPE | £20,000 |
| Gilead | £25,000 |
| BMS | £20,000 |
| BMS | £15,000 |
| BMS | £20,000 |
| BMS | £15,000 |
| BMS | £10,000 |
| BRISTOL-MYERS SQUIBB BELGIUM | £15,000 |